Ligand increases offer for Neurogen
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals is to pay Neurogen an additional $600,000 in an amendment to the merger agreement that rescued the cash-stricken neurological and psychiatric drug developer.